ALK and neoplasm: Ten ALK-positive NSCLC patients and 17 ALK-negative NSCLC patients were included, and the immunohistochemical staining results showed that TF was predominantly expressed at the tumor site in ALK-positive NSCLC (Fig. 2.A).